Realseq develops groundbreaking RNA fragmentomics technology to allow real-time detection of disease, dramatically improving diagnosis and treatment. Ribomarkers are next-generation cell-free (cf)RNA fragmentomics-based diagnostics that are dynamic reporters able to predict dissemination of disease. We are developing and commercializing a liquid biopsy platform for debilitating fungal pathogens such as Valley Fever that are currently poorly managed yet rapidly increasing due to factors such as climate change with global implications. Our core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy).